“…Although it lacks absolute tumour specificity because of the presence of a member of immunologically closely related antigens, such as nonspecific crossreacting antigen (NCA) (von Kleist et al, 1972;Mach & Pusztaszeri, 1972), CEA has been used as an important clinical tumour marker (Tate, 1982). By molecular cloning of cDNA and genomic sequences, primary structures of CEA and NCA were deduced, and revealed that CEA (Oikawa et al, 1987a;Zimmermann et al, 1987;Kamarck et al, 1987;Beauchemin et al, 1987) and NCA (Oikawa et al, 1987b;Tawaragi et al, 1988;Neumaier et al, 1988) have quite similar nucleotide sequences and structures which belong to the immunoglobulin superfamily (Oikawa et al, 1987c;Paxton et al, 1987). The cell surface expression of CEA has been shown to be that of a phosphatidylinositol glycan (PI-G) anchored protein (Hefta et al, 1988;Takami et al, 1988;Hefta et al, 1990), which was cleaved by phosphatidylinositol-specific phospholipase C (PI-PLC) (Ikezawa et al, 1983) similar to Thy-I molecule (Low & Kincade, 1985), the most primitive molecule in the immunoglobulin superfamily.…”